Todd Carter, PhD, Chief Scientific Officer at Voyager Therapeutics, Inc., Cambridge, MA, explains the continued relevance of tau-targeting immunotherapies for the treatment of Alzheimer’s disease (AD), despite recent negative outcomes in clinical trials. Dr Carter talks about the recent accelerated approval of anti-amyloid drugs and how this provides hope that intravenous antibody treatments can have a therapeutic impact in AD. Regarding tau, new antibodies are in development that are more specific to pathological tau and bind in different regions to those previously trialed. Ab01, the lead anti-tau antibody candidate from Voyager Therapeutics, Inc., targets the c-terminal region. Delivery of the antibodies into the brain at a sufficient concentration to have a therapeutic effect is also key to success and may have hindered prior investigational antibodies. Importantly, evidence continues to support the crucial role of tau in neurodegeneration and cognitive decline, implicating it as a valuable drug target. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Todd Carter is an employee of Voyager Therapeutics.